首页> 外文OA文献 >Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8+ T cell responses
【2h】

Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8+ T cell responses

机译:通过皮肤靶向,干包衣,密集包装的微突出物阵列(Nanopatch)进行的流感核蛋白DNA疫苗诱导有效的抗体和CD8 + T细胞反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DNA vaccines have many advantages such as thermostability and the ease and rapidity of manufacture; for example, in an influenza pandemic situation where rapid production of vaccine is essential. However, immunogenicity of DNA vaccines was shown to be poor in humans unless large doses of DNA are used. If a highly efficacious DNA vaccine delivery system could be identified, then DNA vaccines have the potential to displace protein vaccines. In this study, we show in a C57BL/6 mouse model, that the Nanopatch, a microprojection array of high density (> 21,000 projections/cm), could be used to deliver influenza nucleoprotein DNA vaccine to skin, to generate enhanced antigen specific antibody and CD8 T cell responses compared to the conventional intramuscular (IM) delivery by the needle and syringe. Antigen specific antibody was measured using ELISA assays of mice vaccinated with a DNA plasmid containing the nucleoprotein gene of influenza type A/WSN/33 (H1N1). Antigen specific CD8 T cell responses were measured ex-vivo in splenocytes of mice using IFN-γ ELISPOT assays. These results and our previous antibody and CD4 T cell results using the Nanopatch delivered HSV DNA vaccine indicate that the Nanopatch is an effective delivery system of general utility that could potentially be used in humans to increase the potency of the DNA vaccines.
机译:DNA疫苗具有许多优势,例如热稳定性以及制造的便捷性。例如,在流感大流行的情况下,必须快速生产疫苗。但是,除非使用大剂量的DNA,否则DNA疫苗的免疫原性在人类中显示很差。如果可以鉴定出一种高效的DNA疫苗输送系统,那么DNA疫苗就有可能取代蛋白质疫苗。在这项研究中,我们在C57BL / 6小鼠模型中证明了Nanopatch是一种高密度(> 21,000个投影/厘米)的微突起阵列,可用于向皮肤输送流感核蛋白DNA疫苗,以产生增强的抗原特异性抗体与通过针头和注射器进行的常规肌内(IM)递送相比,CD8 T细胞的反应更为明显。使用接种了含有A / WSN / 33型流感病毒核蛋白基因(H1N1)核蛋白基因的DNA质粒的小鼠进行ELISA分析,测量了抗原特异性抗体。使用IFN-γELISPOT分析离体测量小鼠脾细胞中的抗原特异性CD8 T细胞应答。这些结果以及我们先前使用Nanopatch递送的HSV DNA疫苗的抗体和CD4 T细胞结果表明,Nanopatch是通用的有效递送系统,可潜在地用于人类以提高DNA疫苗的效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号